PFM Health Sciences, LP

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$936.4M2026 Q3+ $66.3M options (notional, not included)
Positions84
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.34.2%

PFM Health Sciences, LP reported 84 positions worth $936.4M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ASND (5.2%). Biggest move: new buy XBI ($38.6M).

10 / 84 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ASNDAscendis Pharma A/S$52.1M5.20%228,868——+20.9%
▸ 2 AXSMAxsome Therapeutics$41.0M4.08%222,102——-25.7%
▸ 3 XBIPutSPDR Series$38.6M notional3.85%244,500———
▸ 4 UTHRUnited Therapeutics$37.5M3.74%69,243——+8.5%
▸ 5 THCTenet Healthcare$32.5M3.24%127,294——+14.1%
▸ 6 INBXInhibrx Biosciences$32.1M3.20%320,331——-22.4%
▸ 7 LLYEli Lilly$29.0M2.89%25,076——+23.7%
▸ 8 NBIXNeurocrine Biosciences$29.0M2.89%204,336——+16.5%
▸ 9 INDVSupernus$26.6M2.65%741,864——+1.2%
▸ 10 SPYSPDR S&P 500$24.7M2.47%32,421——-3.0%

Pro Feature

The remaining 74 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does PFM Health Sciences, LP hold as of Q3 2026?

PFM Health Sciences, LP reported 84 positions worth $936.4M in its Q3 2026 13F filing. Largest positions: ASND (5.2%), AXSM (4.1%), XBI (3.8%), UTHR (3.7%) and THC (3.2%).

What did PFM Health Sciences, LP buy in Q3 2026?

New positions: XBI, SPY, CNMD, TEVA and ZBH (27 in all). Added to: INDV, UTHR, ABT, BBIO and AMRX (26 in all).

What did PFM Health Sciences, LP sell in Q3 2026?

Reduced: JAZZ, HUM, LLY, ICLR and UNH (29 in all). Sold out entirely: PEN, SYK, MTD, MRK and LNTH (41 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.